November 17, 2023, Cytek BioSciences Inc (NASDAQ: CTKB) trading session started at the price of $5.91, that was 1.87% jump from the session before. During the day, the shares moved up to $6.04 and dropped to $5.75 before settling in for the closing price of $5.87. A 52-week range for CTKB has been $3.80 – $14.85.
During the last 5-year period, the sales growth of Healthcare Sector giant was 42.14%. When this article was written, the company’s average yearly earnings per share was at -390.00%. With a float of $116.21 million, this company’s outstanding shares have now reached $135.37 million.
Let’s determine the extent of company efficiency that accounts for 583 employees. In terms of profitability, gross margin is +61.92, operating margin of -0.73, and the pretax margin is +0.77.
Cytek BioSciences Inc (CTKB) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cytek BioSciences Inc stocks. The insider ownership of Cytek BioSciences Inc is 14.27%, while institutional ownership is 56.90%. The most recent insider transaction that took place on Nov 07, was worth 86,800. In this transaction President and CEO of this company sold 20,000 shares at a rate of $4.34, taking the stock ownership to the 5,275,796 shares. Before that another transaction happened on Oct 24, when Company’s Chief Financial Officer sold 3,000 for $4.68, making the entire transaction worth $14,040. This insider now owns 96,084 shares in total.
Cytek BioSciences Inc (CTKB) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/29/2023, it has been observed that the corporation posted $0 earnings per share (EPS) during the time that was less than consensus figure (set at $0.03) by -$0.03. This company achieved a net margin of +1.57 while generating a return on equity of 0.62. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -390.00% per share during the next fiscal year.
Cytek BioSciences Inc (NASDAQ: CTKB) Trading Performance Indicators
You can see what Cytek BioSciences Inc (CTKB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.06. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.10, a number that is poised to hit 0.02 in the next quarter and is forecasted to reach 0.01 in one year’s time.
Technical Analysis of Cytek BioSciences Inc (CTKB)
Looking closely at Cytek BioSciences Inc (NASDAQ: CTKB), its last 5-days average volume was 1.4 million, which is a jump from its year-to-date volume of 1.0 million. As of the previous 9 days, the stock’s Stochastic %D was 95.98%. Additionally, its Average True Range was 0.37.
During the past 100 days, Cytek BioSciences Inc’s (CTKB) raw stochastic average was set at 37.72%, which indicates a significant decrease from 97.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.82% in the past 14 days, which was higher than the 53.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.43, while its 200-day Moving Average is $8.26. However, in the short run, Cytek BioSciences Inc’s stock first resistance to watch stands at $6.10. Second resistance stands at $6.21. The third major resistance level sits at $6.39. If the price goes on to break the first support level at $5.81, it is likely to go to the next support level at $5.63. Now, if the price goes above the second support level, the third support stands at $5.52.
Cytek BioSciences Inc (NASDAQ: CTKB) Key Stats
There are 135,549K outstanding shares of the company, which has a market capitalization of 810.59 million. As of now, sales total 164,040 K while income totals 2,580 K. Its latest quarter income was 48,000 K while its last quarter net income were -6,460 K.